# **ASTRIA CONNECTION**

August 2023

## HAEA National Summit 2023

In July, HAEA held its biennial National Summit in Orlando, Florida.

It was incredible and powerful to see members of the HAEA and the HAE community gathered in-person for the first time in four years to celebrate this year's theme, "Living Beyond Boundaries." We felt privileged to connect with people with HAE, caregivers, healthcare professionals, and industry partners who all have a common goal: to build awareness of HAE and discuss how to further improve community members' quality of life.

We were thrilled that our team was able to participate in the Summit and, in addition to hosting a booth, we presented a poster, "People Living with Hereditary Angioedema (HAE) Prioritize Attack-Free Status as a Target for Therapeutic Efficacy." You can view the poster <u>here</u>.

Thank you to everyone who attended the Summit, stopped by our booth, and shared their experiences with us. We are so grateful for your stories, which guide everything we do here at Astria!

Check out some photos from the event to the right.

# Upcoming Events from HAEA/HAEi:

September 1-3, 2023: 2023 HAEi Regional Conference EMEA in Munich, Germany

March 15-17, 2024 2024 HAEi Regional Conference Americas in Panama City, Panama September 12, 2023: 2023 US HAEA Virtual Capitol Hill Day

October 3-6, 2024: 2024 HAEi Global Leadership Workshop in Copenhagen, Denmark



#### **Community Perspective:**

#### Hannah

Hereditary Angioedema Type I

How has preventative treatment changed your life with HAE?

"There are some days that I don't even think about [HAE]. It doesn't even cross my mind. Having that security and knowing that I'm doing something to prevent it and keep my symptoms away, it's great. It allowed me to travel through Australia and study abroad and not be afraid that I'm going to be in a foreign country. It just gives you a sense of security."



#### **ALPHA-STAR Trial**

The ALPHA-STAR trial is a proof-of-concept Phase 1b/2 trial evaluating single and multiple doses of STAR-0215 in people living with HAE types I and II. It is evaluating safety and tolerability, HAE attack rate, pharmacokinetics, pharmacodynamics, and quality of life in the enrolled participants.

Learn more about the ALPHA-STAR trial and our trial sites by visiting https://astriatx.com/for-patients/alpha-star-trial/.

### Stay in touch!

Want the latest Astria Connection sent straight to your inbox? Click <u>here</u> to subscribe.

For advocacy questions: <u>advocacy@astriatx.com</u> Follow us on social media: **@AstriaTx** 



🔰 (in) (O

The information provided here is for those affected by HAE and caregivers. STAR-0215 is in preclinical development and not approved in any territory.